Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CDK14 | O94921 | 6/20 | 0.41 |
| ▸ | CCNY | Q8ND76 | 6/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12992949 | 0.92 | MEN1 (0.40) | POLBJAK2JAK1TYK2ROCK2 | |
| SCHEMBL16692881 | 0.91 | KMT2A (0.44) | POLBCDK14CCNYJAK2JAK1 | |
| SCHEMBL8221053 | 0.90 | POLB (0.45) | POLBP2RX7CDK14CCNYJAK2 | |
| SCHEMBL12992867 | 0.86 | NPC1 (0.43) | POLBROCK1CCNA2CDK2MEN1 | |
| SCHEMBL8219739 | 0.82 | MEN1 (0.43) | POLBCDK14CCNYJAK2JAK1 | |
| SCHEMBL8214920 | 0.81 | KMT2A (0.48) | POLBCDK14CCNYKMT2A | |
| SCHEMBL1645592 | 0.78 | JAK2 (0.52) | POLBCDK14CCNYJAK2JAK1 | |
| SCHEMBL12993202 | 0.78 | CCNA2 (0.51) | CCNA2CDK2 | |
| SCHEMBL3587804 | 0.77 | MEN1 (0.47) | POLBCDK14CCNYJAK2JAK1 | |
| SCHEMBL955039 | 0.76 | MEN1 (0.49) | POLBJAK2JAK1TYK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256106-B1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | ASTEX THERAPEUTICS LTD (GB) | 2015-05-06 | — | — | EP | disclosed |